T. Ohno

Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients

H. Ogata, A. Yokoyama, K. Masuhara, 1996, Cancer Chemotherapy and Pharmacology.

Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure.

T. Sumiyoshi, M. Nagayama, K. Hanada, 2010, Biological & pharmaceutical bulletin.

High-performance liquid chromatographic analysis of unchanged cis-diamminedichloroplatinum (cisplatin) in plasma and urine with post-column derivatization.

K. Masuhara, K. Someya, M. Kinoshita, 1990, Journal of chromatography.

Population Pharmacokinetics and Pharmacodynamics of Cisplatin in Patients with Cancer: Analysis with the NONMEM Program

T. Igarashi, H. Ogata, A. Yokoyama, 1998, Journal of clinical pharmacology.

Enantioselective and highly sensitive determination of carvedilol in human plasma and whole blood after administration of the racemate using normal-phase high-performance liquid chromatography.

T. Sumiyoshi, M. Nagayama, K. Hanada, 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Dermatofibrosarcoma Protuberans

I. Sugano, H. Fujimoto, K. Kozawa, 1996, Acta radiologica.

New method for bioavailability assessment of slow-release preparations of theophylline

H. Hirayama, Y. Kasuya, Hidenori Takahashi, 1985, Journal of Pharmacokinetics and Biopharmaceutics.